Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials.
Se Young ChoiMoon Soo HaJung Hoon KimByung Hoon ChiJin-Wook KimIn Ho ChangTae-Hyoung KimSoon Chul MyungPublished in: Investigative and clinical urology (2022)
Low-dose BCG had more unfavorable outcomes than did standard-dose BCG in terms of recurrence. Tumor progression, cancer-specific survival, and overall survival were similar between the doses. Low-dose BCG improved adverse effects and withdrawal. In the setting of BCG shortage, low-dose BCG may have strong potential as an alternative.